RecruitingNot ApplicableNCT06239974

Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM)

Randomised Controlled Trial of Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM)

Sponsor

The University of Hong Kong

Enrollment

94 participants

Start Date

Sep 1, 2024

Study Type

INTERVENTIONAL

Conditions

Chest Pain

Summary

This is a randomised controlled trial to determine the effectiveness of Vericiguat to improve stress myocardial blood flow (MBF) and myocardial perfusion reserve as measured by cardiac magnetic resonance (CMR) imaging.

Eligibility

Min Age: 40 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Stress Cardiac Magnetic Resonance and a drug called Vericiguat for people with chest pain. The study is currently recruiting participants at 1 location. People eligible for this study include aged 40 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVericiguat

Patients will be prescribed vericiguat once a day for 6 months, starting at 2.5mg and titrated up to the full dose of 10mg per day (doubling of dose every 2 weeks) in addition to optimised medical therapy and standard follow-up like the control group

DIAGNOSTIC_TESTStress Cardiac Magnetic Resonance

All patients will have stress CMR examinations at recruitment and at the end of trial.